Shares of diagnostics company Castle Biosciences Inc. (CSTL) are down more than 70% from their 52-week high of $78.92, recorded last June, and trade around $22.
The company's current portfolio consists of tests for skin cancers, uveal melanoma, Barrett's esophagus and mental health conditions. DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM are some of the test offerings. A couple of research and development programs for tests in other diseases with high clinical needs are also underway.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.